(Q34650482)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588839%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588839%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588839%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Ezia Bello

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588839%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Maurizio D'Incalci

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588839%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1

Michela Romano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588839%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

3

Monique Zangarini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588839%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

5

Luca Porcu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588839%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Carlos M Galmarini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588839%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Luis F García-Fernández

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588839%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Carmen Cuevas

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588839%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Paola Allavena

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588839%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Eugenio Erba

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588839%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

English

0 references

publication date

25 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588839%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Cancer

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588839%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

133

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588839%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588839%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

2024-2033

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588839%20AND%20SRC:MED&resulttype=core&format=json

Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.

28 February 2020

cites work

1 reference

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

21 January 2018

1 reference

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

21 January 2018

1 reference

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

21 January 2018

1 reference

Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.

21 January 2018

1 reference

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

21 January 2018

1 reference

Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin

21 January 2018

1 reference

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

21 January 2018

1 reference

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

21 January 2018

1 reference

Xeroderma pigmentosum genes: functions inside and outside DNA repair

21 January 2018

1 reference

XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids.

21 January 2018

1 reference

The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent

21 January 2018

1 reference

Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.

21 January 2018

1 reference

Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.

21 January 2018

1 reference

Role of homologous recombination in trabectedin-induced DNA damage

21 January 2018

1 reference

PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity

21 January 2018

1 reference

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks.

21 January 2018

1 reference

Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines

21 January 2018

1 reference

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

21 January 2018

1 reference

Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells

21 January 2018

1 reference

Stepwise neoplastic transformation of a telomerase immortalized fibroblast cell line

21 January 2018

1 reference

Reduced expression of the ROCK inhibitor Rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cells

21 January 2018

1 reference

Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways

21 January 2018

1 reference

Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways

21 January 2018

1 reference

Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex

21 January 2018

1 reference

Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells

21 January 2018

1 reference

Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition.

21 January 2018

1 reference

Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin

21 January 2018

1 reference

Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer

21 January 2018

1 reference

Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production

21 January 2018

1 reference

Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.

21 January 2018

1 reference

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

21 January 2018

1 reference

Role of Macrophage Targeting in the Antitumor Activity of Trabectedin

21 January 2018

1 reference